Katakura Industries (3001) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2025, increased by 5.4% year-over-year to ¥30,145 million, driven by strong performance in the machinery segment despite a decline in pharmaceuticals.

• Operating income rose 53.6% year-over-year to ¥4,803 million, and net income attributable to shareholders surged 90.4% to ¥4,870 million, aided by gains from fixed asset sales.

• The company continues to focus on structural reforms, business expansion, and strengthening its foundation for sustainable growth.

Financial highlights

• Operating income: ¥4,803 million (up 53.6% year-over-year).

• Ordinary income: ¥5,737 million (up 42.4% year-over-year).

• Net income attributable to shareholders: ¥4,870 million (up 90.4% year-over-year).

• EPS: ¥152.38 (up from ¥77.87 year-over-year).

• Comprehensive income: ¥6,787 million (up 115.4% year-over-year).

Outlook and guidance

• Full-year revenue forecast: ¥40,700 million (up 3.2% year-over-year).

• Full-year operating income forecast: ¥5,000 million (up 21.2% year-over-year).

• Full-year net income forecast: ¥4,900 million (up 39.0% year-over-year).

• No change to previously announced earnings guidance.

• Dividend forecast revised upward to ¥60 per share.